Literature DB >> 14585261

Classification of anticancer drugs--a new system based on therapeutic targets.

Enrique Espinosa1, Pilar Zamora, Jaime Feliu, Manuel González Barón.   

Abstract

The arrival of a great number of new antineoplastic agents has made it necessary to reclassify all of them. Anticancer drugs may act at different levels: cancer cells, endothelium, extracellular matrix, the immune system or host cells. The tumour cell can be targeted at the DNA, RNA or protein level. Most classical chemotherapeutic agents interact with tumour DNA, whereas monoclonal antibodies and small molecules are directed against proteins. The endothelium and extracellular matrix may be affected also by specific antibodies and small molecules.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585261     DOI: 10.1016/s0305-7372(03)00116-6

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  30 in total

Review 1.  Studies on anticancer activities of antimicrobial peptides.

Authors:  David W Hoskin; Ayyalusamy Ramamoorthy
Journal:  Biochim Biophys Acta       Date:  2007-11-22

Review 2.  The DNA-damage response in human biology and disease.

Authors:  Stephen P Jackson; Jiri Bartek
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

Review 3.  ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

Authors:  Young Hee Choi; Ai-Ming Yu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 4.  Applicability of the comet assay in evaluation of DNA damage in healthcare providers' working with antineoplastic drugs: a systematic review and meta-analysis.

Authors:  Mohammad Javad Zare Sakhvidi; Mohammad Hajaghazadeh; Mehrdad Mostaghaci; Amir Houshang Mehrparvar; Fariba Zare Sakhvidi; Elham Naghshineh
Journal:  Int J Occup Environ Health       Date:  2016-04-25

Review 5.  Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Authors:  Tarek Magdy; Brian T Burmeister; Paul W Burridge
Journal:  Pharmacol Ther       Date:  2016-09-05       Impact factor: 12.310

Review 6.  Therapy-induced chemoexosomes: Sinister small extracellular vesicles that support tumor survival and progression.

Authors:  Shyam K Bandari; Kaushlendra Tripathi; Sunil Rangarajan; Ralph D Sanderson
Journal:  Cancer Lett       Date:  2020-08-26       Impact factor: 8.679

Review 7.  Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs.

Authors:  Sabrina Riedl; Dagmar Zweytick; Karl Lohner
Journal:  Chem Phys Lipids       Date:  2011-09-16       Impact factor: 3.329

8.  Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis.

Authors:  S Ranjbar; O Firuzi; N Edraki; O Shahraki; L Saso; M Khoshneviszadeh; R Miri
Journal:  Medchemcomm       Date:  2017-08-23       Impact factor: 3.597

9.  Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon cancer.

Authors:  Wagdy M Eldehna; Rofaida Salem; Zainab M Elsayed; Tarfah Al-Warhi; Hamada R Knany; Rezk R Ayyad; Thamer Bin Traiki; Maha-Hamadien Abdulla; Rehan Ahmad; Hatem A Abdel-Aziz; Radwan El-Haggar
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 10.  Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.

Authors:  Shan-Shan Qi; Jia-Hui Sun; Hao-Han Yu; Shu-Qin Yu
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.